

# Jose A Cortes-Briones

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5134432/publications.pdf>

Version: 2024-02-01

29  
papers

828  
citations

567281

15  
h-index

713466

21  
g-index

30  
all docs

30  
docs citations

30  
times ranked

1201  
citing authors

#	ARTICLE	IF	CITATIONS
1	Rapid Changes in Cannabinoid 1 Receptor Availability in Cannabis-Dependent Male Subjects After Abstinence From Cannabis. <i>Biological Psychiatry: Cognitive Neuroscience and Neuroimaging</i> , 2016, 1, 60-67.	1.5	135
2	Efficacy and safety of a fatty acid amide hydrolase inhibitor (PF-04457845) in the treatment of cannabis withdrawal and dependence in men: a double-blind, placebo-controlled, parallel group, phase 2a single-site randomised controlled trial. <i>Lancet Psychiatry</i> , 2019, 6, 35-45.	7.4	125
3	Reduced Brain Cannabinoid Receptor Availability in Schizophrenia. <i>Biological Psychiatry</i> , 2016, 79, 997-1005.	1.3	83
4	$\delta^9$ -THC Disrupts Gamma ( $\gamma$ )-Band Neural Oscillations in Humans. <i>Neuropsychopharmacology</i> , 2015, 40, 2124-2134.	5.4	57
5	It's All in the Rhythm: The Role of Cannabinoids in Neural Oscillations and Psychosis. <i>Biological Psychiatry</i> , 2016, 79, 568-577.	1.3	54
6	Targeting the ecology within: The role of the gut-brain axis and human microbiota in drug addiction. <i>Medical Hypotheses</i> , 2016, 93, 77-80.	1.5	50
7	The Psychosis-like Effects of $\delta^9$ -Tetrahydrocannabinol Are Associated With Increased Cortical Noise in Healthy Humans. <i>Biological Psychiatry</i> , 2015, 78, 805-813.	1.3	44
8	Going deep into schizophrenia with artificial intelligence. <i>Schizophrenia Research</i> , 2022, 245, 122-140.	2.0	39
9	Cannabinoids and Psychosis. <i>Current Pharmaceutical Design</i> , 2017, 22, 6380-6391.	1.9	39
10	Preliminary in vivo evidence of lower hippocampal synaptic density in cannabis use disorder. <i>Molecular Psychiatry</i> , 2021, 26, 3192-3200.	7.9	32
11	GABA Deficits Enhance the Psychotomimetic Effects of $\delta^9$ -THC. <i>Neuropsychopharmacology</i> , 2015, 40, 2047-2056.	5.4	29
12	The dose-dependent psychomotor effects of intravenous delta-9-tetrahydrocannabinol ( $\delta^9$ -THC) in humans. <i>Journal of Psychopharmacology</i> , 2018, 32, 1308-1318.	4.0	27
13	Going up in Smoke? A Review of nAChRs-based Treatment Strategies for Improving Cognition in Schizophrenia. <i>Current Pharmaceutical Design</i> , 2014, 20, 5077-5092.	1.9	25
14	Cannabinoid receptor-mediated disruption of sensory gating and neural oscillations: A translational study in rats and humans. <i>Neuropharmacology</i> , 2018, 135, 412-423.	4.1	23
15	Psychosis-Relevant Effects of Intravenous Delta-9-Tetrahydrocannabinol: A Mega Analysis of Individual Participant-Data from Human Laboratory Studies. <i>International Journal of Neuropsychopharmacology</i> , 2020, 23, 559-570.	2.1	23
16	Cannabinoid-glutamate interactions and neural oscillations: implications for psychosis. <i>European Journal of Neuroscience</i> , 2018, 48, 2890-2902.	2.6	17
17	Highs and lows of cannabinoid-dopamine interactions: effects of genetic variability and pharmacological modulation of catechol-O-methyl transferase on the acute response to delta-9-tetrahydrocannabinol in humans. <i>Psychopharmacology</i> , 2019, 236, 3209-3219.	3.1	8
18	Characterizing psychosis-relevant phenomena and cognitive function in a unique population with isolated, chronic and very heavy cannabis exposure. <i>Psychological Medicine</i> , 2020, 50, 2452-2459.	4.5	8

#	ARTICLE	IF	CITATIONS
19	Testing differences in the activity of event-related potential sources: Important implications for clinical researchers. <i>Clinical Neurophysiology</i> , 2015, 126, 215-218.	1.5	3
20	Electroencephalography and Cannabis. , 2016, , 851-862.		2
21	Psychotomimetic and Cognitive Effects of $\Delta^9$ -Tetrahydrocannabinol in Laboratory Settings. , 2018, , 75-128.		2
22	Hearing the Shape of a Drum: Clinical Outcome Prediction in Participants at Clinical High-Risk for Psychosis With the 40-Hz Auditory Steady-State Response Paradigm. <i>Biological Psychiatry</i> , 2021, 90, 359-361.	1.3	2
23	17.2 EFFICACY OF CANNABIDIOL IN THE TREATMENT OF EARLY PSYCHOSIS.. <i>Schizophrenia Bulletin</i> , 2018, 44, S27-S27.	4.3	1
24	63. Cannabinoid-Mediated Disruption of Sensory Gating and Neural Network Oscillations: A Translational Study in Humans and Rats. <i>Biological Psychiatry</i> , 2017, 81, S26-S27.	1.3	0
25	67. Ketamine-induced Changes in Neural Noise and their Relationship to Psychosis-like Symptoms. <i>Biological Psychiatry</i> , 2017, 81, S28.	1.3	0
26	168. The Effect of Fatty Acid Amide Hydrolase Inhibition on Sleep Architecture in Cannabis Withdrawal. <i>Biological Psychiatry</i> , 2018, 83, S68.	1.3	0
27	20.1 BEHAVIORAL, COGNITIVE, AND PSYCHOPHYSIOLOGICAL CHARACTERIZATION AND SHORT-TERM COURSE OF CANNABINOID- INDUCED ACUTE PERSISTENT PSYCHOSIS (CIAPP). <i>Schizophrenia Bulletin</i> , 2019, 45, S121-S122.	4.3	0
28	O11.2. CHARACTERIZING CANNABINOID INDUCED ACUTE PERSISTENT PSYCHOSIS (CIAPP) AS A POSSIBLE SUBTYPE OF SCHIZOPHRENIA USING DEEP LEARNING. <i>Schizophrenia Bulletin</i> , 2019, 45, S194-S194.	4.3	0
29	Delta-9-Tetrahydrocannabinol, Cannabidiol, and Acute Psychotomimetic States: A Balancing Act of the Principal Phyto-Cannabinoids on Human Brain and Behavior. <i>Cannabis and Cannabinoid Research</i> , 2022, , .	2.9	0